Cargando…

Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury

Coagulopathy management is an important strategy for preventing secondary brain damage in patients with traumatic brain injury (TBI). Antithrombin (AT) is a natural anticoagulant that controls coagulation and inflammation pathways. However, the significance of AT activity levels for outcomes in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masaki, Wada, Takeshi, Nakae, Ryuta, Fujiki, Yu, Kanaya, Takahiro, Takayama, Yasuhiro, Suzuki, Go, Naoe, Yasutaka, Yokobori, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558212/
https://www.ncbi.nlm.nih.gov/pubmed/36248813
http://dx.doi.org/10.3389/fimmu.2022.981826
_version_ 1784807389625581568
author Takahashi, Masaki
Wada, Takeshi
Nakae, Ryuta
Fujiki, Yu
Kanaya, Takahiro
Takayama, Yasuhiro
Suzuki, Go
Naoe, Yasutaka
Yokobori, Shoji
author_facet Takahashi, Masaki
Wada, Takeshi
Nakae, Ryuta
Fujiki, Yu
Kanaya, Takahiro
Takayama, Yasuhiro
Suzuki, Go
Naoe, Yasutaka
Yokobori, Shoji
author_sort Takahashi, Masaki
collection PubMed
description Coagulopathy management is an important strategy for preventing secondary brain damage in patients with traumatic brain injury (TBI). Antithrombin (AT) is a natural anticoagulant that controls coagulation and inflammation pathways. However, the significance of AT activity levels for outcomes in patients with trauma remains unclear. This study aimed to investigate the relationship between AT activity levels and long-term outcomes in patients with TBI; this was a sub-analysis of a prior study that collected blood samples of trauma patients prospectively in a tertiary care center in Kawaguchi City, Japan. We included patients with isolated TBI (iTBI) aged ≥16 years admitted directly to our hospital within 1 h after injury between April 2018 and March 2021. General coagulofibrinolytic and specific molecular biomarkers, including AT, were measured at 1, 3, 6, 12, and 24 h after injury. We analyzed changes in the AT activity levels during the study period and the impact of the AT activity levels on long-term outcomes, the Glasgow Outcome Scale-Extended (GOSE), 6 months after injury. 49 patients were included in this study; 24 had good neurological outcomes (GOSE 6–8), and 25 had poor neurological outcomes (GOSE 1–5). Low AT activity levels were shown within 1 h after injury in patients in the poor GOSE group; this was associated with poor outcomes. Furthermore, AT activity levels 1 h after injury had a strong predictive value for long-term outcomes (area under the receiver operating characteristic curve of 0.871; 95% CI: 0.747–0.994). Multivariate logistic regression analysis with various biomarkers showed that AT was an independent factor of long-term outcome (adjusted odds ratio: 0.873; 95% CI: 0.765–0.996; p=0.043). Another multivariate analysis with severity scores showed that low AT activity levels were associated with poor outcomes (adjusted odds ratio: 0.909; 95% CI: 0.822–1.010; p=0.063). We demonstrated that the AT activity level soon after injury could be a predictor of long-term neurological prognosis in patients with iTBI.
format Online
Article
Text
id pubmed-9558212
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95582122022-10-14 Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury Takahashi, Masaki Wada, Takeshi Nakae, Ryuta Fujiki, Yu Kanaya, Takahiro Takayama, Yasuhiro Suzuki, Go Naoe, Yasutaka Yokobori, Shoji Front Immunol Immunology Coagulopathy management is an important strategy for preventing secondary brain damage in patients with traumatic brain injury (TBI). Antithrombin (AT) is a natural anticoagulant that controls coagulation and inflammation pathways. However, the significance of AT activity levels for outcomes in patients with trauma remains unclear. This study aimed to investigate the relationship between AT activity levels and long-term outcomes in patients with TBI; this was a sub-analysis of a prior study that collected blood samples of trauma patients prospectively in a tertiary care center in Kawaguchi City, Japan. We included patients with isolated TBI (iTBI) aged ≥16 years admitted directly to our hospital within 1 h after injury between April 2018 and March 2021. General coagulofibrinolytic and specific molecular biomarkers, including AT, were measured at 1, 3, 6, 12, and 24 h after injury. We analyzed changes in the AT activity levels during the study period and the impact of the AT activity levels on long-term outcomes, the Glasgow Outcome Scale-Extended (GOSE), 6 months after injury. 49 patients were included in this study; 24 had good neurological outcomes (GOSE 6–8), and 25 had poor neurological outcomes (GOSE 1–5). Low AT activity levels were shown within 1 h after injury in patients in the poor GOSE group; this was associated with poor outcomes. Furthermore, AT activity levels 1 h after injury had a strong predictive value for long-term outcomes (area under the receiver operating characteristic curve of 0.871; 95% CI: 0.747–0.994). Multivariate logistic regression analysis with various biomarkers showed that AT was an independent factor of long-term outcome (adjusted odds ratio: 0.873; 95% CI: 0.765–0.996; p=0.043). Another multivariate analysis with severity scores showed that low AT activity levels were associated with poor outcomes (adjusted odds ratio: 0.909; 95% CI: 0.822–1.010; p=0.063). We demonstrated that the AT activity level soon after injury could be a predictor of long-term neurological prognosis in patients with iTBI. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9558212/ /pubmed/36248813 http://dx.doi.org/10.3389/fimmu.2022.981826 Text en Copyright © 2022 Takahashi, Wada, Nakae, Fujiki, Kanaya, Takayama, Suzuki, Naoe and Yokobori https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Takahashi, Masaki
Wada, Takeshi
Nakae, Ryuta
Fujiki, Yu
Kanaya, Takahiro
Takayama, Yasuhiro
Suzuki, Go
Naoe, Yasutaka
Yokobori, Shoji
Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title_full Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title_fullStr Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title_full_unstemmed Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title_short Antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
title_sort antithrombin activity levels for predicting long-term outcomes in the early phase of isolated traumatic brain injury
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558212/
https://www.ncbi.nlm.nih.gov/pubmed/36248813
http://dx.doi.org/10.3389/fimmu.2022.981826
work_keys_str_mv AT takahashimasaki antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT wadatakeshi antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT nakaeryuta antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT fujikiyu antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT kanayatakahiro antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT takayamayasuhiro antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT suzukigo antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT naoeyasutaka antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury
AT yokoborishoji antithrombinactivitylevelsforpredictinglongtermoutcomesintheearlyphaseofisolatedtraumaticbraininjury